SecBot SecBot
SECBOTREPLAY Home › Report › MYGN

MYGN · Q3 rev $202.7M, Prenatal sale

MYRIAD GENETICS INC · 8-K filed Nov 4, 2026 at 16:07 ET

At the news

MIXEDIMPACT 6/10

8-K filed Nov 4, 2026 at 16:07 ET

Myriad Genetics reported Q3 2026 revenue of $202.7M, above the $191.3M consensus, but GAAP net loss widened to $43.9M ($0.46 per share) from $27.4M a year ago. The company raised the mid-point of its full-year 2026 revenue guidance to $780M-$790M and announced a definitive agreement to sell its Prenatal Health business to Labcorp for $210M in cash, expected to close by early 2027.

  • Q3 2026 revenue $202.7M, up 6% sequentially but down 1% YoY, above the $191.3M consensus
  • GAAP net loss $43.9M ($0.46 per share) vs $27.4M loss a year ago; adjusted loss per share $0.11
  • Full-year 2026 revenue guidance raised to $780M-$790M (mid-point raised from $870M prior range, reflecting the Prenatal divestiture)
  • Definitive agreement to sell Prenatal Health business to Labcorp for $210M cash plus inventory value, expected to close by early 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access